May 14, 2020 / 9:24 AM / in 16 days

BRIEF-Innate Pharma To Present New Data For Monalizumab In Combination With Cetuximab In Head And Neck Cancer

May 14 (Reuters) - INNATE PHARMA SA:

* TO PRESENT NEW EFFICACY DATA FOR MONALIZUMAB IN COMBINATION WITH CETUXIMAB IN HEAD AND NECK CANCER AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAL

* PHASE II EXPANSION COHORT OF “IO-PRETREATED PATIENTS” DEMONSTRATES 20% OVERALL RESPONSE RATE

* DATA CONFIRM PREVIOUS PRELIMINARY EFFICACY DATA SEEN IN THIS SUBPOPULATION Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below